Category: Q2Syndicate content

Philips' healthcare business suffers in Q2

July 28, 2014 by Arezu Sarvestani

Sluggish healthcare sales drag down Philips overall figures, but the company is eying a comeback for the 2nd half of the year.

Philips' healthcare business suffers in Q2

Philips Healthcare (NYSE:PHG) had a tough 2nd quarter with a shutdown of a manufacturing facility in Cleveland taking some of the wind out of the sales for the entire company.

AtriCure renews outlook on another strong quarter

July 25, 2014 by Arezu Sarvestani

AtriCure gets some Wall Street love after again boosting its full-year expectations on the back of a 30% boost in revenues in its 2nd quarter.

AtriCure renews outlook on another strong quarter

Ohio-based AtriCure (NSDQ:ATRC) gained a few points today as investors reacted to new of the company's Q2 financial report.

Bard: We're on track for early 2015 Lutonix approval

July 25, 2014 by Brad Perriello

Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.

Bard: We're on track for early 2015 Lutonix approval

C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.

Covidien's Q3 sales meet The Street, earnings top estimates

July 25, 2014 by Brad Perriello

Covidien's fiscal 3rd-quarter sales come in dead even with expectations on Wall Street as its earnings top analysts' consensus estimate.

Covidien's Q3 sales meet The Street, earnings top estimates

Zimmer slides on Q2 sales miss, lowered outlook

July 24, 2014 by Brad Perriello

Zimmer Holdings misses 2nd-quarter sales expectations, just meets Wall Street's earnings forecast and cuts its 2014 guidance, sending share prices down this morning.

Zimmer slides on Q2 sales miss

Zimmer (NYSE:ZMH) shares are down this morning after the orthopedic device maker reported disappointing 2nd-quarter results and cut its outlook for the rest of the year.

Boston Scientific beats The Street with Q2 sales, earnings

July 24, 2014 by Brad Perriello

Boston Scientific beats Wall Street's expectations and its own forecasts for 2nd-quarter sales and earnings, with strong performances from its core implantable cardiac defibrillator and drug-eluting stent businesses.

Boston Scientific beats The Street with Q2 sales, earnings

Ex-Stryker CFO Hartman takes over at ConMed

July 23, 2014 by Arezu Sarvestani

ConMed names former Stryker CFO Curt Hartman interim CEO and lowers its outlook for the rest of the year.

Former Styker CFO takes over at ConMED

Surgical device maker ConMed (NSDQ:CNMD) took a major hit on Wall Street today after announcing some turnover at the top and lowering its financial outlook for the rest of the year.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp